Tyra Biosciences
TYRA
164 hedge funds and large institutions have $2.52B invested in Tyra Biosciences in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 14 closing their positions.
229% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 14
69% more capital invested
Capital invested by funds: $1.49B → $2.52B (+$1.03B)
69% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 35
23% more funds holding
Funds holding: 133 → 164 (+31)
15.93% more ownership
Funds ownership: 106.47% → 122.41% (+16%)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
64% less call options, than puts
Call options by funds: $4.2M | Put options by funds: $11.6M
Top Buyers
Top Sellers
TYRA Hedge Fund Activity: Q1 2026 in Review
164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2026, worth a combined $2.52B — up 69% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new TYRA positions and 14 closed out — a net gain of 32 holders — while 59 added to existing stakes and 35 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $250M. The largest seller was Canaan Partners XI, cutting an estimated $85M.
- 164 institutional investors held Tyra Biosciences (TYRA) as of Q1 2026, up from 133 in Q4 2025.
- Funds reported $2.52B of Tyra Biosciences stock for Q1 2026, up 69% quarter-over-quarter.
- 46 funds opened new Tyra Biosciences positions in Q1 2026 and 14 closed out, a net change of +32 holders.
- The largest Tyra Biosciences buyer in Q1 2026 was Fidelity Investments, an estimated $250M added.
- The largest Tyra Biosciences seller in Q1 2026 was Canaan Partners XI, an estimated $85M sold.
Based on aggregated 13F filings for Q1 2026.